États-Unis · Bourse & Finance · Reuters Business

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

Publié par Reuters Business · États-Unis il y a 11 h

Australia's CSL said on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to ‌co-develop and co-promote a treatment for rare kidney and liver…

Lire l'article complet sur Reuters Business Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.reuters.com)

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

À lire aussi

They survived World War II and lost decades, but not 2026. Japan's century-old businesses are disappearing at a record pace

Zcash gets a Washington lobbyist to push crypto policy

Air Force removes all bombers from British base and redeploys them to the U.S. after a planned terror attack linked to Iran was foiled

Fuel Price Shock Pushes Global Gas Car Sales Below 50% for First Time

P.&G.’s Chief on Whether Brand Loyalty Is Enough When Prices Keep Climbing

Sam Altman said 'the world should accept some bad things happening' for the benefits of AI

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

Partager

À lire aussi

They survived World War II and lost decades, but not 2026. Japan's century-old businesses are disappearing at a record pace

Zcash gets a Washington lobbyist to push crypto policy

Air Force removes all bombers from British base and redeploys them to the U.S. after a planned terror attack linked to Iran was foiled

Fuel Price Shock Pushes Global Gas Car Sales Below 50% for First Time

P.&G.’s Chief on Whether Brand Loyalty Is Enough When Prices Keep Climbing

Sam Altman said 'the world should accept some bad things happening' for the benefits of AI